Avalo Therapeutics, Inc.
AVTX- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001534120
In the last 90 days, Avalo Therapeutics, Inc. insiders filed 0 open-market purchases and 8 sales; 126 institutions reported holding it in 13F filings for Q2 2026, worth $1.31B in total; no superinvestor holds it.
Q2 2024 vs. Q1 2024
How the institutions holding Avalo Therapeutics, Inc. changed between Q1 2024 and Q2 2024.
All holders in Q2 2024All holders in Q1 2024
| Measure | Q1 2024 | Q2 2024 | Change |
|---|---|---|---|
| Holders | 18 | 21 | +3 |
| Shares | 87.5K | 771.1K | +683.6K (+781.2%) |
| Value | $1.90M | $9.62M | +$7.72M (+406.6%) |
New holders (7)
Institutions that held Avalo Therapeutics, Inc. at the end of Q2 2024 but not at the end of Q1 2024.
| Institution | Shares | Value | % of portfolio |
|---|---|---|---|
| Logos Global Management LP | 539,079 | $6.72M | 0.77% |
| Commodore Capital LP | 40,000 | $498.8K | 0.03% |
| Vanguard Group Inc | 10,368 | $129.3K | 0.00% |
| Bank of America Corp | 5,601 | $69.8K | 0.00% |
| FMR LLC | 2 | $25 | 0.00% |
| Key Financial Inc | 1 | $12 | 0.00% |
| Activest Wealth Management | 1 | $12 | 0.00% |
Sold out (4)
Institutions that held Avalo Therapeutics, Inc. at the end of Q1 2024 and filed for Q2 2024 without it.
| Institution | Shares, Q1 2024 | Value, Q1 2024 |
|---|---|---|
| ADAR1 Capital Management, LLC | 6,000 | $130.5K |
| Natixis | 2,512 | $54.6K |
| Tower Research Capital LLC (TRC) | 1,640 | $35.7K |
| Old Point Trust & Financial Services N A | 1 | $22 |